Rakovina Therapeutics Provides Update on Previously Announced Private Placement

VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies, announces that, further to the press releases dated May 23, 2024, June 20, 2024 and July 19, 2024, the Company has received subscriptions for an aggregate of $2,000,000 worth of units of the Company and has issued and closed on 19,200,000 units. Read More

Rakovina Therapeutics Provides Update on Previously Announced Private Placement

Rakovina Therapeutics Provides Update on Previously Announced Private Placement

Rakovina Therapeutics Provides Update on Previously Announced Private Placement

Rakovina Therapeutics Provides Update on Previously Announced Private Placement

Rakovina Therapeutics Provides Update on Previously Announced Private Placement